digital currency review, Block

In addition to the integrated circuit design industry, Shanghai will also set up a M&A fund for the biomedical industry with a scale of 10 billion yuan.A 10 billion yuan M&A fund for biomedical industry will also be set up.The "10 billion yuan M&A fund for integrated circuit design industry" stated in the Action Plan is considered by the market as a supplement to the 100 billion yuan parent fund for the three leading industries.

Since then, after continuing to Shenzhen and Anhui, Shanghai has also made efforts in mergers and acquisitions.Bu Rixin said that only through mergers and acquisitions and accelerating industrial integration can the benign development of the industry be promoted, which is also one of the most effective measures.Big move! Shanghai's 10 billion integrated circuit design industry M&A fund has come.

"The government's participation in M&A fund investment does not mean that the government will dominate the M&A business, but encourage market-oriented institutions and chain owners to lead the M&A business through the above-mentioned M&A fund or parent fund support." Bu Rixin believes.The science and technology innovation board Journal reporter noted that over the past year, a number of semiconductor companies have indeed terminated the IPO process. For example, Chengdu Ruiyuan Semiconductor Technology Co., Ltd. terminated its IPO nearly 10 months after the meeting. In addition, more than 20 companies in the semiconductor industry also voluntarily withdrew their materials to terminate the IPO after being inspected on the spot.Biomedicine, as one of the leading industries in Shanghai, has a scale of nearly one trillion yuan. In 2023, the industrial scale reached 933.732 billion yuan, an increase of 4.9%; Shanghai's biomedical industry chain is relatively complete, with many medical device enterprises and CRO, CMO and CSO enterprises. Therefore, Yuan Shuai believes that the Shanghai Municipal Government will set up a 10 billion yuan M&A fund for biomedical industry, which is expected to cultivate internationally competitive biomedical enterprises through mergers and acquisitions.